C.R.Bard, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Receives 510(k) clearance for its Memotherm Flexx biliary stent for treating malignant biliary obstructions. The firm recently completed the initial phase of a feasibility study for the Memotherm carotid stent and plans to pursue a compassionate use approval from FDA while it develops a distal protection program